Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 14 of the 83 sources its claims cite were checked for support.
Abstract
For decades, self-monitoring of blood glucose (SMBG) has been considered a cornerstone of adequate diabetes management. Structured SMBG can follow different monitoring patterns, and it results in improved glycemic control, reduced hypoglycemia, and a better quality of life of people with diabetes. The technology, usability, and accuracy of SMBG systems have advanced markedly since their introduction a few decades ago. Current SMBG systems are small and easy to use, require small (capillary) blood sample volumes, and provide measurement results within seconds. In addition, devices are increasingly equipped with features such as connectivity to other devices and/or digital diaries and diabetes management tools. Although measurement quality can come close to or equal that of the glucose monitoring systems used by healthcare professionals, several available SMBG systems still do not meet internationally accepted accuracy standards, such as the International Organization for Standardization 15197 standard. Reports from China, India, and Brazil based on local experience suggest that in addition of the accuracy issues of SMBG systems, other obstacles also need to be overcome to optimize SMBG usage. Nonetheless, adequate usage of SMBG data is of high relevance for the management of people with type 2 diabetes mellitus.
Overview
CoChat Summary
TL;DR
This narrative review argues that self-monitoring of blood glucose (SMBG) remains an integral, beneficial component of type 2 diabetes management, especially when structured and actively used to guide therapy. It summarizes SMBG technology, accuracy standards, and local access/education barriers from China, India, and Brazil.
Key findings
- Structured SMBG can improve glycemic control, reduce hypoglycemia, and improve quality of life; in non-insulin-treated T2DM, benefit is linked to actively using blood glucose values for treatment decisions or therapy adjustments.
- Independent accuracy evaluations show many marketed SMBG systems still fail international standards: only 33% of evaluated systems met ISO 15197:2013 requirements in Klonoff et al., whereas 77% met them in Pleus et al.
- Local reports show major access and adherence problems: China had 140 million adults with diabetes in 2021, prevalence rose from 10.9% in 2013 to 13.2% in 2020, and most (>70%) did not adhere to recommended SMBG frequency/timing; India had 74 million people with diabetes in 2021, projected to reach 92 million by 2030 and 124 million by 2045, with 80% paying out of pocket; Brazil had 15.7 million people with diabetes in 2021, with only 26% of public-system patients achieving HbA1c <7% versus 40% in private clinics.
- Barriers include high out-of-pocket costs, insufficient self-management education and empowerment, limited access, and cultural beliefs; modern SMBG systems increasingly offer connectivity, digital diaries, reminders, and pattern analysis to support therapy.
Methods
- Narrative review based on previously conducted studies; the authors state it contains no new studies with human participants or animals.
- Synthesizes literature on SMBG systems, accuracy standards, diabetes management tools, and local experience reports from China, India, and Brazil.
- No systematic review, meta-analysis, or primary data collection is described; the paper includes tables and figures illustrating structured testing profiles and accuracy plots.
Limitations
- The paper states that it is based on previously conducted studies and does not contain new studies with human participants or animals.
- The text does not report a systematic search strategy, inclusion/exclusion criteria, or formal risk-of-bias assessment; this is evident from the article format.
- Some local data are described as unpublished or based on local experience, which may limit generalizability; this is evident from the India and local-experience sections.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 a Difference plot showing methods comparisons for two systems for SMBG with higher (green squares) and lower (red triangles) levels of accuracy. The orange lines reflect the accuracy requirements of the current ISO 15197:2015 standard [21], i.e., 95% of measurements need to fall within up to ± 0.8 mmol/L (± 15 mg/dL) or ± 15% from the comparison method (for values < 5.6 mmol/L [< 100 mg/dL] or ≥ 5.6 mmol/L [≥ 100 mg/dL]). b Scatter plot of SMBG systems with higher (green squares) and lower (red triangles) levels of accuracy](https://figures.cochat.ai/paper-figures/e2fec321857f4135a79fd1cd76eb9630/self-monitoring-of-blood-glucose-as-an-integral-part-in-the-management-of-people-figure-2.jpg)
Verification
Claims the paper makes
8 Valid · 2 Not valid · 51 Not checked · 47 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Structured SMBG can follow different monitoring patterns, and it results in improved glycemic control, reduced hypoglycemia, and a better quality of life of people with diabetes.”
- Also stated in: § Current Situation and Outlook · boosted
“The benefits of structured SMBG in terms of improved glycemic control and quality of life for people with T2DM have been shown repeatedly [4, 5].”
§ Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus > Abstract
What the sources say
- Partly supportedcites [4] Mannucci E, Antenore A, Giorgino F, Scavini M. Effects of structured versus unstructured self-monitoring of blood glucose on glucose control in patients with non-insulin-treated type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Sci Technol. 2018;12:183–9. https://doi.org/10.1177/1932296817719290. sourceExperimental — accuracy not yet measured
The Abstract (p. 1) reports a greater HbA1c reduction with structured than unstructured SMBG, and the Conclusions (p. 6) say its glucose-control benefits are more evident when SMBG data guide treatment adjustments. The evidence is limited to people with non-insulin-treated type 2 diabetes, rather than people with diabetes generally. (LLM, conf=0.86)
- Not checked yetcites [5] Schnell O, Alawi H, Battelino T, Ceriello A, Diem P, Felton AM, et al. Self-monitoring of blood glucose in type 2 diabetes: recent studies. J Diabetes Sci Technol. 2013;7:478–88. https://doi.org/10.1177/193229681300700225. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Current Situation and Outlook · boosted
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, while the use of CGM systems has been shown to (further) improve therapy for people with T1DM [12, 13], mixed results have been reported on the use of CGM systems by people with T2DM [14, 15].”
§ Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus > Current Situation and Outlook
What the sources say
- Supportedcites [14] Janapala RN, Jayaraj JS, Fathima N, et al. Continuous glucose monitoring versus self-monitoring of blood glucose in type 2 diabetes mellitus: a systematic review with meta-analysis. Cureus. 2019;11: e5634. https://doi.org/10.7759/cureus.5634. source
The Discussion reports that most studies found reduced HbA1c with CGM in T2DM, while one found no significant change. It also notes that some studies found no significant difference in other outcomes, supporting the characterization of results as mixed. (LLM, conf=0.93)
- Not checked yetcites [15] Lin R, Brown F, James S, Jones J, Ekinci E. Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus. Diabet Med. 2021;38: e14528. https://doi.org/10.1111/dme.14528. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, there are also studies with conflicting data, leading to contrary conclusions, that have shown no or only a short-term benefit (≤ 6 months) of structured BG measurements for people with diabetes not on insulin therapy [6–8].”
§ Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus > Current Situation and Outlook
What the sources say
- Partly supportedcites [6] Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;1:Cd005060. https://doi.org/10.1002/14651858.CD005060.pub3. sourceExperimental — accuracy not yet measured
The Main results report a small HbA1c benefit at six months but no statistically significant benefit at 12 months for non-insulin-treated patients whose type 2 diabetes had lasted at least one year. The claim is broader than that finding: the Implications for practice section says newly diagnosed patients benefited, and the review evaluates self-monitoring of blood glucose generally rather than only structured measurements. (LLM, conf=0.86)
- Partly supportedcites [7] Farmer AJ, Perera R, Ward A, et al. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ. 2012;344:e486. https://doi.org/10.1136/bmj.e486. sourceExperimental — accuracy not yet measured
The paper concludes that self-monitoring in non-insulin-treated type 2 diabetes did not show a convincing clinically meaningful effect, supporting the claim of limited benefit. However, the Results report a small but statistically significant HbA1c reduction at 12 months, so this source does not support limiting the observed benefit to six months or less. The interventions also varied rather than uniformly using structured measurements. (LLM, conf=0.88)
- Supportedcites [8] O’Kane MJ, Bunting B, Copeland M, Coates VE. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ. 2008;336:1174–7. https://doi.org/10.1136/bmj.39534.571644.BE. source
The Abstract identifies insulin treatment as an exclusion criterion. The Results describe a scheduled self-monitoring regimen, and Outcome measures reports no significant difference in HbA1c between monitoring and control groups at any time point through 12 months. This study therefore supports the cited sentence’s 'no benefit' alternative; it does not report a short-term benefit. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, difference plots have certain advantages in comparison to scatter plots [31]; for example, scatter plots show only a correlation between two variables, not their differences.”
§ Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus > SMBG Systems > Accuracy Evaluations
What the sources say
- Partly supportedcites [31] Giavarina D. Understanding Bland Altman analysis. Biochem Med (Zagreb). 2015;25:141–51. https://doi.org/10.11613/BM.2015.015. sourceExperimental — accuracy not yet measured
The Correlation and linear regression section says correlation describes the relationship between two sets of measurements, not their agreement, supporting the contrast with a difference plot. But the Bland and Altman method section explicitly calls its difference plot a scatter plot, so the source does not support the unqualified claim that scatter plots show only correlation and never differences (page numbers unavailable). (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although this analysis only captures patterns obtained from SMBG measurements, and thus the patterns are highly dependent on the frequency and timing of the measurements, it allows clinicians and patients to make better informed therapeutic adjustments [36].”
§ Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus > Diabetes Management and the Role of SMBG
What the sources say
- Supportedcites [36] Parkin CG, Davidson JA. Value of self-monitoring blood glucose pattern analysis in improving diabetes outcomes. J Diabetes Sci Technol. 2009;3:500–8. source
The Abstract says that analyzing patterns in SMBG data facilitates rational therapeutic adjustments. The Background also describes using those patterns to identify glycemic excursions, take appropriate action, and assess the effects of therapeutic changes. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 2 with their cited sources checked
Create a free account to see all 108 claims and to verify the 69 references still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 37
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Regular self-monitoring (tracking) helps informed decision-making [17-19].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus > Current Situation and Outlook
“| Monday | X | | X | | X | | X | Pre- and postprandial BG measurements for 1 meal on 2 days or overnight |”
§ Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus > Current Situation and Outlook
“| Tuesday | | X | | X | | X | | Pre- and postprandial BG measurements for 1 meal on 2 days or overnight |”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
International Organization for Standardization
(2011) · SpringerReference · doi:10.1007/springerreference_16847 · Cited by 12,534
Understanding bland altman analysis
Giavarina, D. (2015) · Biochemia Medica · doi:10.11613/bm.2015.015 · Cited by 4,706 · cited 1×
“However, difference plots have certain advantages in comparison to scatter plots [31]; for example, scatter plots show only a correlation between two variables, not their differences.”
BackgroundDiretrizes da Sociedade Brasileira de Diabetes: 2011
de Diabetes, S. B. (2011) · Cited by 2,362
Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013
Wang, L., Gao, P., Zhang, M., Huang, Z., Zhang, D., Deng, Q., Li, Y., Zhao, Z., Qin, X., Jin, D., et al. (2017) · JAMA · doi:10.1001/jama.2017.7596 · Cited by 1,844
Artificial intelligence for diabetes management and decision support: Literature review
Contreras, I., & Vehi, J. (2018) · Journal of Medical Internet Research · doi:10.2196/10775 · Cited by 560
Polonsky, W. H., Fisher, L., Schikman, C. H., Hinnen, D. A., Parkin, C. G., Jelsovsky, Z., Petersen, B., Schweitzer, M., & Wagner, R. S. (2011) · Diabetes Care · doi:10.2337/dc10-1732 · Cited by 429
Diabetes mellitus and its complications in India
Unnikrishnan, R., Anjana, R. M., & Mohan, V. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.53 · Cited by 393 · cited 1×
“The majority of PwD in India ([95%) have T2DM; the remaining PwD have various forms of diabetes, including T1DM, gestational diabetes mellitus, fibrocalculous pancreatic diabetes, among other forms [48].”
BackgroundSelf-citationSelf-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin
Malanda, U. L., Welschen, L. M., Riphagen, I. I., Dekker, J. M., Nijpels, G., & Bot, S. D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005060.pub3 · Cited by 358
Research works printed but not linked: 3
- International Diabetes Federation. IDF diabetes atlas 10th edition 2021. 2021. https://diabetesatlas.org/data/en/. Accessed 09 Dec 2021.
- Chinese Diabetes Society. Guideline for clinical use of blood glucose monitoring (2015). Chin J Diabetes Mellitus. 2015;7:603–13.
- Indian Council of Medical Research. ICMR guidelines for management of type 2 diabetes. Delhi: Indian Council of Medical Research; 2018.
Cited by
Eichenlaub, M., Pleus, S., Rothenbühler, M., Bailey, T. S., Bally, L., Brazg, R., Bruttomesso, D., Diem, P., Boija, E. E., Fokkert, M. J., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0465 · Cited by 55
“43 In addition, we recommend that the participants should perform the measurements in duplicate from the same finger prick.”
Self-citationThe Evolution of Diabetes Technology – Options Toward Personalized Care
Zahid, M., Dowlatshahi, S., Kansara, A., & Sadhu, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.007 · Cited by 24
The Development, Characteristics, and Challenges of Biosensors: The Example of Blood Glucose Meters
Chen, H., & Chen, C. (2025) · Chemosensors · doi:10.3390/chemosensors13080300 · Cited by 18
Yang, Y., Tan, J., He, Y., Huang, H., Wang, T., Gong, J., Liu, Y., Zhang, Q., & Xu, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099302 · Cited by 16
Real-World Diabetes Technology: Overcoming Barriers and Disparities
Messer, L. H., Addala, A., & WEINZIMER, S. A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2511 · Cited by 15
Metadata
- Authors
- Pleus, S., Freckmann, G., Schauer, S., Heinemann, L., Ziegler, R., Ji, L., Mohan, V., Calliari, L. E., & Hinzmann, R.
- Affiliations
- Universität Ulm (DE)
- Peking University People's Hospital (CN)
- Madras Diabetes Research Foundation (IN)
- Roche Diabetes Care GmbH (Germany) (DE)
- Corresponding author
- Hinzmann, Rolf
- ORCID
- Venue
- Diabetes Therapy
- Published
- 2022-04-13
- Volume
- 13
- Issue
- 5
- Pages
- 829-846
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC9076772
- OpenAlex
- W4223596170
- Semantic Scholar
- 050eb63041d33655e416d3511ebf7e9c1a558ae4
- Cited by
- 55
- References
- 59
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 14 · 2023: 10
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Roche Diabetes Care GmbH
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- self-monitoring of blood glucose, type 2 diabetes, glycemic control, hypoglycemia, ISO 15197, digital health devices, diabetes management, quality of life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1007/s13300-022-01254-8
- The paper
- Pleus, S., Freckmann, G., Schauer, S., Heinemann, L., Ziegler, R., Ji, L., Mohan, V., Calliari, L. E., & Hinzmann, R. (2022). Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus. Diabetes Therapy. https://doi.org/10.1007/s13300-022-01254-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.